Table 2. Changes in Physical Activity During 12 Months After Randomization.
| Exercise Vital Signa | Participants, No. (%) | Adjusted P Values | ||||||
|---|---|---|---|---|---|---|---|---|
| Standard Care (n = 1349) | WO (n = 1358) | WO-P (n = 321) | SC vs WOb | SC vs WO-Pc | ||||
| Baseline | 12 mo | Baseline | 12 mo | Baseline | 12 mo | |||
| Inactive, 0 min/wk | 890 (66.0) | 819 (60.7) | 911 (67.1) | 808 (59.5) | 208 (64.8) | 162 (50.5) | .34 | <.001 |
| Insufficiently active, 1-149 min/wk | 262 (19.4) | 243 (18.0) | 245 (18.0) | 268 (19.7) | 67 (20.9) | 83 (25.9) | ||
| Active, ≥150 min/wk | 160 (11.9) | 171 (12.7) | 174 (12.8) | 182 (13.4) | 43 (13.4) | 69 (21.5) | ||
| Missingd | 37 (2.7) | 116 (8.6) | 28 (2.1) | 100 (7.4) | 3 (0.9) | 7 (2.2) | ||
| Any physical activity | ||||||||
| 0 min/wk | 927 (68.7) | 935 (69.3) | 939 (69.1) | 908 (66.9) | 211 (65.7) | 169 (52.6) | .16 | <.001 |
| >0 min/wk | 422 (31.3) | 414 (30.7) | 419 (30.9) | 450 (33.1) | 110 (34.3) | 152 (47.4) | ||
| Meet physical activity guidelines | ||||||||
| 0-149 min/wk | 1189 (88.1) | 1178 (87.3) | 1184 (87.2) | 1176 (86.6) | 278 (86.6) | 252 (78.5) | .73 | <.01 |
| ≥150 min/wk | 160 (11.9) | 171 (12.7) | 174 (12.8) | 182 (13.4) | 43 (13.4) | 69 (21.5) | ||
Abbreviations: SC, standard care; WO, Walk On!; WO-P, Walk On! participants.
Exercise vital sign values include all available data in the 12 months before and 12 months after the randomization date and are summarized as the median or modal value.
Intent-to-treat multinomial logistic regression analyses adjusted for age, forced expiratory volume in the first second of expiration predicted, Charlson Comorbidity Index, oxygen use, hospitalization for chronic obstructive pulmonary disease in the previous 12 months, outpatient-treated chronic obstructive pulmonary disease exacerbation in the previous 12 months, length of time since acute care use to randomization, use of long-acting β-2 agonist or inhaled corticosteroids, physical activity level, and study site.
As-treated multinomial logistic regression analyses used stabilized propensity score inverse probability of treatment weighting to balance baseline characteristics (sociodemographics, health behaviors, disease severity, comorbidities, inhalers/medications, clinical biomarkers, and health care use in the prior year) between patients who participated in Walk On! and the SC group.
Missing 12-month, postrandomization exercise vital sign for SC and WO (n = 216) due to not having an encounter during the year (85 [39.4%]) or exercise vital sign not captured during any encounter (131 [60.6%]).